Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?
BACKGROUND The increase in serum C-reactive protein ( CRP ) levels is an independent determinant of cardiovascular events in long-term hemodialysis ( HD ) patients . Recently , statins have shown anti-inflammatory properties in addition to their lipid-lowering effect . METHODS We design ed a 6-month , prospect i ve , r and omized , controlled study to assess the safety and efficacy of atorvastatin in reducing serum CRP levels in long-term HD patients . Patients on HD therapy for at least 6 months , with autologous vascular access , were included . Patients presenting with illnesses and /or use of drugs that may affect CRP levels were excluded . After r and omization , group A included 16 patients treated with atorvastatin ( 10 mg/d orally ) , and group B included 17 patients treated with placebo .  Body mass index , Kt/V , normalized protein catabolic rate , mean blood pressure , and levels of hemoglobin , serum CRP , albumin , creatinine , lipids , and enzymes were recorded at baseline and after 6 months . RESULTS Qualitative/quantitative parameters were homogeneous between the groups at baseline . In group A , median serum CRP levels decreased from 9 mg/L ( range , 5 to 22 mg/L ) at baseline to 5 mg/L ( range , 3 to 16 mg/L ) after 6 months ( P = 0.004 ) . In group B , values were 8 mg/L ( range , 4 to 14 mg/L ) at baseline and 7 mg/L ( range , 3 to 17 mg/L ) after 6 months ( P = 0.98 ) . Serum CRP levels were lower in group A than group B at month-4 ( 5 mg/L ; range , 3 to 11 mg/L versus 7 mg/L ; range , 3 to 10 mg/L , respectively ; P = 0.054 ) and month-6 evaluations ( 5 mg/L ; range , 3 to 16 mg/L versus 7 mg/L ; range , 3 to 17 mg/L , respectively ; P = 0.060 ) . After 6 months , only in group A was there a significant decrease in serum cholesterol levels ( P = 0.041 ) and a significant increase in serum albumin levels ( P = 0.004 ) . Enzyme levels were stable during the study in both groups . CONCLUSION Administration of atorvastatin is safe in patients on long-term HD therapy and , in addition to its beneficial effects on lipid levels , induces a significant decrease in serum CRP levels , with a consequential increase in serum albumin  levels
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .